News and Trends 26 Jan 2023 New tool to fight antibiotic resistance The World Health Organization (WHO) ranks antibiotic resistance as one of the top 10 threats to global health. In response, researchers at Chalmers University of Technology in Sweden have developed a new spray that can kill antibiotic-resistant bacteria, and that can be used for wound care and directly on implants and other medical devices. “Our […] January 26, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 26 Jan 2023 Scopio on the future of telehematology Through full-field digital cell morphology, Scopio Labs’ technology can automate the analysis of tens of thousands of cells at a time. This could mean bringing earlier detection and diagnosis of cancers, infections, and other diseases, expediting patients’ access to better care and life-saving treatments. Erez Na’aman, co-founder and CTO of Scopio Labs, tells us about […] January 26, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 Lupus treatment hope from Japanese miRNA research A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. They identified two miRNAs that are downregulated in the disease and an uncommon situation that occurs in which multiple miRNAs regulate the same set of genes. Although […] January 26, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 First patient treated in Atrogi type 2 diabetes clinical study Atrogi AB, an early-stage Swedish pharma company, has announced that the first patient has been enrolled in a phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class novel b2 adrenoceptor agonist with a unique mechanism of action for the treatment of type 2 diabetes and comorbidities. This approach is supported by data […] January 26, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 Sysnav and Roche partner on movement tracking technology Sysnav Healthcare and Roche have partnered to develop industry standard outcome measurements in diseases associated with movement impairments, as well as designing the next generation of wearable technology based on Sysnav’s technology. Patients living with a neuromuscular disorder often suffer from movement impairments that fundamentally impact their daily life. Reliable, objective measurements of a patient’s […] January 26, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 Ibex to collaborate with AstraZeneca and Daiichi Sankyo on AI breast cancer product Ibex Medical Analytics has announced an agreement with AstraZeneca and Daiichi Sankyo, for the development, clinical validation and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry (IHC) scoring in breast cancer patients. Scoring of HER2 (human epidermal growth factor receptor 2) protein expression in breast […] January 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 Milestone for gene-edited therapy for sickle cell disease Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics have announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application of exa-cel for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The submission is supported by two global phase 3 studies investigating exa-cel as a potential one-time therapy for people with […] January 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 Alcohol-related liver disease: mechanism could lead to new therapies Alcohol-related liver disease is among the most common causes of morbidity and mortality worldwide. Due to an incomplete understanding of the factors contributing to disease development, liver transplantation is still the only available cure. A team led by Tim Hendrikx from MedUni Vienna’s Department of Laboratory Medicine has now uncovered a new mechanism that plays […] January 24, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 First leukemia patient dosed with SMART101 Smart Immune has announced that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial SloanKettering Cancer Center (MSK). The phaseI/II trial is a multicenter, open-label, first-in-human study expected to enroll up to 36 adult and pediatric patients with hematological malignancies, […] January 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 Ubiquigent and University of Glasgow to collaborate on drug discovery Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neruodegenerative, renal, and cardiovascular diseases. Overseen by structural biology experts […] January 24, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 Funding for university to develop new motor neuron disease therapies Medical research charity LifeArc, the Motor Neurone Disease Association (MND Association) and the My Name’5 Doddie Foundation have jointly awarded £1 million ($1.2 million) to researchers at University College London (UCL) to progress two pioneering new therapies that could help transform the lives of those living with motor neuron disease (MND). The research grants are […] January 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 CytoReason expands deal with Sanofi to look at IBD CytoReason, which creates computational disease modeling, has announced an expansion of its collaboration with Sanofi. The multi-year collaboration will further fuel Sanofi’s target discovery efforts via CytoReason’s AI platform in the field of inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets. In 2021, Cytoreason announced the initiation of a […] January 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email